Metabolic dysfunction-associated fatty liver and antiviral response in chronic hepatitis B: A systematic review and meta-analysis

Figure 2 Forest plots comparing hepatitis B surface antigen seroclearance rates between patients with chronic hepatitis B alone and those with chronic hepatitis B and metabolic dysfunction-associated fatty liver disease. A: 48 weeks; B: 96 weeks, C: 48 weeks, nucleos(t)ide analogues therapy; D: 48 weeks, interferon-based therapy; E: 96 weeks, nucleos(t)ide analogues therapy; F: 96 weeks, interferon-based therapy. Pooled effects are expressed as odds ratios with 95%CIs. MAFLD: Metabolic dysfunction-associated fatty liver disease; CHB: Chronic hepatitis B.